the plasma of patients revealed a reduction of multimeric forms and a reduced ability to bind the natural receptor tunica interna endothelial cell kinase 2 of the ANGPT1 p.A119S variant. The recombinant mutated ANGPT1 p.A119S formed a reduced amount of multimers and showed reduced binding capability to its receptor. Conclusion: ANGPT1 impairment is associated with angioedema, and ANGPT1 variants can be the basis of HAE. (J Allergy Clin Immunol 2018;141:1009-17.)
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Hereditary angioedema (HAE) is a rare genetic disease with an estimated prevalence in the general population of approximately 1:50,000. It is characterized by localized and self-limiting edema of the subcutaneous and/or submucosal tissue due to a temporary increase in vascular permeability caused by the release of vasoactive mediators. The clinical expression is highly variable, from asymptomatic cases to patients with disabling and lifethreatening attacks, and it has a demonstrated humanistic and economic burden. 1 The most common form is hereditary angioedema caused by C1 inhibitor deficiency (C1-INH-HAE; Online Mendelian Inheritance in Man [OMIM] #106100). Two variants have been described, both characterized by normal activity of C1 inhibitor (C1-INH) in plasma. One is identified by mutations in the coagulation Factor XII gene (F12), coagulation Factor XII (FXII)-HAE (OMIM #610618), 2 and the other with a yet unknown genetic defect (hereditary angioedema with yet unknown genetic defect [U-HAE]) shows penetrance and symptoms very similar to those of C1-INH-HAE. 3 Because of HAE morbidity and mortality, appropriate treatment is mandatory but thus far available only for C1-INH-HAE, the pathophysiology of which is clearly defined: the upregulation of the contact activation system/ kallikrein-kinin system, which is inhibited at several points by C1-INH, results in an increase in bradykinin levels and appearance of recurrent angioedema. 1 The same mediator appears responsible for HAE caused by F12 deficiency, 4 and based on the pathophysiology, several treatment options could be effective, including C1-INH agents and bradykinin-targeted drugs. 5, 6 To date, because no causative variants have been described for U-HAE, the pathophysiology of the disease remains obscure, 1, 3 and the therapeutic approach remains elusive.
We have investigated a large cohort of Italian patients with familial and sporadic U-HAE recruited from the Italian Network for C1-INH-HAE (ITACA), and in a large family we have identified a missense variant in the angiopoietin-1 gene (ANGPT1) that affects the protein's abilities to recognize its natural receptor tunica interna endothelial cell kinase 2 (TIE2) on endothelial cells, suggesting a novel and independent mechanism leading to vascular permeability and angioedema.
METHODS Patients
Twenty-five patients belonging to 10 independent families and 22 additional unrelated index patients with U-HAE recruited from ITACA were enrolled for the study. 7 All patients presented with familial angioedema symptoms and fulfilled the criteria for U-HAE, as described by Cicardi et al. 1 We evaluated the participants' clinical and family history, and in all patients we searched for C1-INH and F12 mutations. After approval of local ethics committees, the study was carried out according to the principles of the Declaration of Helsinki; informed consent was obtained from all subjects.
Nailfold capillaroscopy
On members of the index family, nailfold capillaroscopy was carried out at the Department of Medical Sciences and Public Health, University of Cagliari, by using a standard protocol. After excluding interfering factors inducing microcirculatory abnormalities, the fourth and fifth digital nail beds were examined on each hand. Patients were interviewed for (1) the presence of signs, symptoms, or both suggestive of a connective tissue disease or a history of Raynaud phenomenon; (2) the use of drugs that might interfere with microcirculation; (3) other conditions that might cause microcirculatory abnormalities (eg, work-related stress neuropathy and carpal tunnel syndrome); and (4) repetitive periungual lesions known to generate artifacts (eg, recent manicure and onychophagia). A video capillaroscope equipped with a 3200 optical probe was used to capture, code, and store images by using Videocap 3.0 software (DS-Medica, Milan, Italy). The fourth and fifth digital nail beds were examined on each hand, with a drop of immersion oil applied to the nailfold before the examination to maximize the translucency of the epidermal layer. The following parameters were assessed: the total number of capillaries per millimeter, the number of capillaries with different morphologies, the presence of microhemorrhages, and subpapillary venous plexus visibility. The patients did not show other detectable cardiac, lymphatic, or skin disorders or other linkable clinical manifestations, as assessed by using echocardiography and vascular, thoracic, and abdominal ultrasound examination.
Genetic studies
We performed genetic analysis of a multiplex Italian family consisting of 12 members in 3 generations with U-HAE using whole-exome sequencing (WES) and direct DNA sequencing. In remaining families and unrelated patients, the genetic analysis was performed by means of direct DNA sequencing. WES was outsourced to GATC Biotech (Konstanz, Germany). Genomic DNA was isolated from peripheral blood leukocytes according to standard protocols, 8 and coding regions were enriched by using the SureSelectXT Human All Exon V5 kit (50MB; Agilent Technologies, Santa Clara, Calif). DNA sequencing was undertaken on the HiSeq2000 platform (Illumina, San Diego, Calif) with 125-bp paired-end reads. Mean coverage was greater than 953 and 51 megabases was the target size that required approximately 4 gigabases of sequencing per sample.
Sequence reads were aligned to the human genome reference sequence (GRCh37/hg19 software (Variant Studio, Illumina). Different approaches were used to minimize the number of potentially deleterious gene defects: (1) hgvs.org/). After using these filtering strategies, the number of variants were reduced to approximately 300 to 400. A functional annotation was undertaken based on the effect on protein function and a priori knowledge of phenotype to further prioritize the candidate gene defects. After this initial prioritization, additional strategies were used to find the causative mutation: (1) the linkage strategy, in which multiple affected family members were sequenced to identify shared variation and unaffected relatives were sequenced to exclude a benign variation, or (2) the overlap strategy, which involves searching for mutations in multiple unrelated patients with a similar phenotype. Variants were validated by means of Sanger sequencing, and segregation analysis of the prioritized variants was performed in additional affected family members when constitutive DNA was available.
Mutational screening of the ANGPT1 coding region and exon/intron boundaries was performed by using direct DNA sequencing. 9 The deleterious effect of the p.A119S substitution was investigated by using in silico prediction, as previously described. 10 Briefly, the in silico pathogenicity prediction and determination of the putative effect of amino acid substitutions on protein structure were performed by using established available bioinformatics tools (Table I) . Moreover, we examined selected variants in the context of biological pathways and disease phenotype with the VarElect NGS phenotyper (http:// varelect.genecards.org/), a tool that can rapidly prioritize genes potentially associated with a particular disease, phenotype, or other biological function based on shared pathways, interaction networks, paralogy relations, domain sharing, and mutual publication. The putative effect of amino acid substitutions on protein structure was evaluated by using the SWISS-MODEL automated protein modeling tool (https://swissmodel.expasy.org) and the Phyre2 Web-based services for protein structure prediction (http://www.sbg.bio.ic. ac.uk/phyre2/html/page.cgi?id5index).
Site-directed mutagenesis and transfection
Site-directed mutagenesis experiments were carried out to insert the identified mutations into a full-length human ANGPT1 complementary DNA plasmid (pCMV6-Vector, Myc-DDK-tagged; OriGene, Rockville, Md) by using the QuikChange II Site-directed Mutagenesis Kit (Agilent Technology), according to the manufacturer's instructions, as previously reported. 11 Three primer pairs containing the desired mutations and flanked unmodified sequence were used, and the presence of desired mutations in selected colonies was verified by means of sequencing. HEK 293T cells were transiently transfected with mutants or wild-type ANGPT1 complementary DNAs. Briefly, 293T cells were seeded onto a T75 flask to obtain 50% to 70% confluence on the following day. Cells were transiently transfected with TurboFectin 8.0 Transfection Reagent, according to the manufacturer's instructions (OriGene). The transfection efficiency was evaluated with the ZOE Cell Fluorescence Imager by using an anti-DDK tag mAb (1:200, OriGene). The supernatant was harvested from transfected cells after 48 hours. Recombinant proteins containing the FLAG sequence were purified by means of column chromatography on anti-FLAG M1 antibody agarose affinity gel (Sigma-Aldrich, St Louis, Mo). After purification of 293T supernatants, recombinant proteins were quantitated by using the Bradford assay and confirmed with Coomassie blue staining of an SDS-PAGE gel. The yield of each recombinant protein was 350 to 400 mg/L of 293T cell supernatant.
Plasma concentrations of ANGPT1 and ANGPT2
Plasma samples were collected by means of a clean venipuncture and minimal stasis with sodium citrate 3.2% after centrifugation at 2000g for 20 minutes at room temperature. Plasma was divided into aliquots and stored at 2808C until testing. The concentration of ANGPT1 and angiopoietin-2 (ANGPT2) was measured in duplicate determinations by using commercially available ELISA kits (R&D Systems, Minneapolis, Minn). The ELISA sensitivity was 156.25 to 10,000 pg/mL for ANGPT1 and 31.1 to 4000 pg/mL for ANGPT2. Mediators were evaluated in 3 family members with the p.A119S variant in remission compared with 4 healthy donors.
Plasma ANGPT1 analysis
Venous blood was collected in tubes containing citrate. Plasma samples were subjected to depletion of albumin and globulin by using the ProteoPrep Blue Albumin and IgG Depletion Kit (Sigma-Aldrich). All steps were performed according to the manufacturer's instructions at equal volumes. Western blot analysis was performed to detect plasma ANGPT1. IgG/human serum albumin-depleted plasma samples were separated by using SDS-PAGE under nonreducing and reducing (10 minutes at 958C in 0.435 mol/L bmercaptoethanol) conditions. The proteins were transferred from the precast gel to a nitrocellulose membrane. Then, the membrane was incubated with anti-ANGPT1 polyclonal antibody (Millipore, Temecula, Calif) certified for detection of ANGPT1 in human plasma (IgG/human serum albumindepleted) lysate. Binding of the recombinant proteins to the soluble extracellular domain TIE2-Fc (Abcam, Cambridge, United Kingdom) was assayed by using an in vitro binding assay as for recombinant proteins.
Characterization of recombinant proteins
SDS-PAGE analyses of proteins were performed under nonreducing and reducing (10 minutes at 958C in 0.435 mol/L b-mercaptoethanol) conditions. Binding of the recombinant proteins to the soluble extracellular domain TIE2-Fc (Abcam) was assayed by using an in vitro binding assay. Each recombinant protein (20 ng) was mixed with 100 ng of sTIE2-Fc and incubated in 500 mL of Tris buffer solution (50 mmol/L Tris and 100 mmol/L NaCl, pH 7.4) containing 0.02% Triton X-100 at 48C for 2 hours. Then 20 mL of Dynabeads Protein A (Thermo Fisher Scientific, Waltham, Mass) was added and incubated for another 1 hour at 48C. Dynabeads Protein A-conjugated samples were washed twice with 1 mL of Tris buffer containing 0.02% Triton X-100. The samples were eluted with sample buffer and heat denatured and then separated further by using 10% SDS-PAGE, electroblotted onto nitrocellulose membranes, and probed with mouse 4 C5 anti-DDK tag antibody.
RESULTS Cohort
Twenty-five patients belonging to 10 independent families and 22 additional unrelated index patients with U-HAE were enrolled. All patients had negative results for C1-INH impairment and F12 mutations. 12 Among them, a multiplex Italian family with angioedema but without urticaria that segregated as an autosomal dominant trait (Fig 1, A) was selected to undergo in-depth genetic investigation by using WES.
Patients had a history of recurrent angioedema since their second decade without any identifiable cause despite extensive investigations. They did not respond to antihistamines and steroids for acute attacks or prophylaxis (Fig 1, B) . Mechanical stimuli (minor traumas and prolonged pressure) provoked only a minority of the attacks, which had a slow onset and resolution. Patients reported about 2 episodes per year lasting 24 to 48 hours (median, 33 hours), mainly involving the skin (face, lips, and oral mucosa) and abdomen. Patient III:2 had severe abdominal attacks for which she underwent repeated endoscopy and unnecessary surgery. Prophylaxis with oral tranexamic acid reduced the number and severity of attacks in patients II:3 and III:2. Nailfold capillaroscopy revealed normal capillary dimensions and density, with slightly ectasic hairpin-shaped loop morphology but many tortuous loops, microhemorrhages, and reduced skin transparency caused by edema in all affected family members but not in asymptomatic relatives (Fig 1, C) . These changes indicate involvement of the microcirculation because of dilatation and increased capillary permeability.
DNA analysis
WES of 2 affected relatives (II:1 and III:2) was performed, assuming a dominant mode of inheritance, and we selected all functional rare heterozygous mutations shared by patients. An ANGPT1 mutation in exon 2 (NM_001146.3:c.807G>T, Chr8 [GRCh37]:g.107347040G>T), predicting a change in the protein (p.A119S; Fig 1, D) , emerged as the most likely candidate to explain the phenotype. The nucleotide and protein-numbering system is based on the nomenclature recommended by the Human Genome Variation Society. The presence of the ANGPT1 p.A119S variant was confirmed by means of direct sequencing of genomic DNA of the patients and was detected in 2 other family members with U-HAE (patients I:1 and II:1) but not in 7 asymptomatic family members (Fig 1, A) . The mutation resulted in a very rare variant and was predicted to have a detrimental effect on protein function (Table I ). The variant was very rare in available databases (Table II) J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 3 cohort direct DNA sequencing analysis showed the presence of 2 rare variants (p.R225C and p.R494Q), each identified in only 1 patient and suggested to have a detrimental effect on protein functionality (Tables I and II) .
Ex vivo protein analysis
Measurements of ANGPT1 and ANGPT2 plasma levels did not show any significant difference between patients and unaffected relatives (Table III) . The amino acid position 119 lies at the end of a region of the coiled-coil domain of the protein (Fig 2, A) crucial for multimerization of ANGPT1. 13 The substitution of a hydrophilic residue for a hydrophobic one was predicted to change the protein structure (Fig 2, B and C) , suggesting a possible important effect on functionality. Multimeric analysis was carried out by immunoblotting of plasma samples under nonreduced and reduced condition. Quantitative analysis revealed a reduction of multimeric forms after normalization for reduced ANGPT1 in patients compared with an unaffected relative (Fig 3, A and B) . In addition, slightly higher amounts of dimeric and trimeric multimers were present in plasma from patients (Fig 3, A) .
Because binding to TIE2 on endothelial cells requires higherorder multimerization, 13, 14 the ability of the mutant protein to bind the natural receptor was investigated by using a soluble form of the receptor (TIE2-Fc chimera protein). In patients carrying the mutated protein, a reduced amount of binding of ANGPT1 was detected compared with that in an unaffected relative (Fig 3, C and D) .
Expression and analysis of mutant ANGPT1
The p.A119S mutation was expressed in HEK 293 cells to confirm the hypothesis that the variant identified affects ANGPT1 multimerization and leads to reduced binding to the TIE2 receptor. In addition, the effects of the 2 additional rare ANGPT1 variants (p.R225C and p.R494Q) identified and predicted to affect protein functionality were investigated (Table I) . Thus we established transient transformants of HEK 293 cells expressing the wild-type and 3 mutant ANGPT1s. Under nonreducing conditions, the recombinant wild-type protein and the mutated p.R225C and p.R494Q variants showed a similar multimerization state, with amounts being largely represented by tetramers and pentamers. In contrast with this finding, the ANGPT1 p.A119S mutant showed a reduced amount of multimers (Fig 4, A and  B) . These findings supported the hypothesis that appropriate multimerization occurred for all preparations, although to a lower degree, about one third, for the p.A119S mutant.
In vitro binding assays revealed that approximately 63% of the total amount of the p.A119S mutant bound to the TIE2-Fc receptor compared with greater than 90% of the total amount of wildtype ANGPT1, p.R225C, and p.R494Q mutants (Fig 4, C and D) . These data mimicked those observed by using native proteins and indicate that binding capability to its receptor derived from the mutant p.A119S was lower than that derived from wild-type ANGPT1.
DISCUSSION
In this study we investigated possible causative genetic defects in samples obtained from Italian families with U-HAE. In one of these families, we identified a novel missense mutation in ANGPT1 (p.A119S) that resulted in a variant protein that was normally processed and secreted. In this family the mutation cosegregated with the clinical phenotype, indicating that it could be the basis of autosomal dominant U-HAE, a pathophysiologic entity distinct from other forms of HAE. Bradykinin mediates angioedema in patients with C1-INH-HAE, and in such patients selective bradykinin B2 receptor antagonists revert angioedema attacks. [15] [16] [17] Recent evidence suggests that bradykinin release by plasmin is facilitated by F12 mutations described in patients with HAE caused by F12 deficiency. 18 The family described in this study suggests that HAE can also derive from a point mutation that impairs the interaction of ANGPT1 with its membrane receptor, TIE2. ANGPT1 has been shown to decrease plasma leakage induced by bradykinin; thus we hypothesize that the ANGPT1 mutant p.A119S is implicated in altered endothelial permeability regulation, thus generating recurrent angioedema, which is bradykinin mediated as with the other HAEs. 19 Results from animal models and patients imply that the ANGPT1-TIE2 axis stabilizes the blood vascular endothelium and regulates barrier function. [20] [21] [22] [23] Indeed, ANGPT1 targets key mechanisms contributing to the maintenance of endothelial barrier function by inhibiting the effects of multiple permeabilityenhancing agents, including vascular endothelial growth factor. 24, 25 In animal models ANGPT1 regulates the integrity of the adult vasculature, protecting from plasma leakage, particularly in patients with inflammatory diseases. 26, 27 ANGPT1 is a secreted protein ligand for TIE2, a receptor primarily expressed in growing vascular endothelial cells. 28 The structure of ANGPT1 consists of a carboxyl terminal fibrinogen-like domain that binds to the TIE2 receptor, a central coiled-coil domain that enables oligomerization of these fibrinogen-like domains, and a short amino-terminal domain that further clusters the oligomers to form multimers. 13 At variance with most other known growth factors, ANGPT1 multimeric structures are crucial to induce the activation of TIE2, whereas dimers and monomers are less able to bind the endothelial cell receptor.
14 The ANGPT1 variant identified in our patients with U-HAE lies within the first portion of the coiled-coil domain. In plasma from patients with HAE, ANGPT1 shows reduced capacity to form multimers and reduced ability to bind the TIE-Fc chimera compared with the protein analyzed from plasma of relatives without angioedema. These abnormalities were confirmed comparing the recombinant A119S variant with recombinant wild-type and 2 naturally occurring rare recombinant variants (p.R225C and p.R494Q), which are located in the coiled-coil and fibrinogen-like domains, respectively. The impairment of protein functionality appears higher when testing the native variant protein from plasma than using the recombinant one.
We do not fully address the mechanism by which the heterozygous variant we characterized exerts its effect. Both an autosomal dominant negative effect and haploinsufficiency of the identified ANGPT1 variant could explain the intermediate phenotype. The difference could be ascribed, at least in part, to an in vivo additional impairment of the mutant protein on the stability of multimers, as suggested by the presence of higher amounts of smaller multimers in patients' plasma.
No gene variants within ANGPT1 were previously associated with human diseases. The gene product plays a pivotal role for developmental angiogenesis, and its complete deficiency is not viable. 29 However, overexpression of ANGPT1 protects from vascular leakage induced by inflammatory agents. 30 Overall, these data are in agreement with our results and support the hypothesis that a partial ANGPT1 impairment is associated with angioedema and that ANGPT1 variants can be identified as the third cause of HAE. In animal studies an important role of ANGPT1 in the activation of mast cells that could be responsible for a therapeutic effect of ANGPT1 on anaphylaxis-related diseases was identified. 31 We have no evidence that the mutation reported in our patients could modify such a ''therapeutic'' effect of ANGPT1. However, recent data point to the possibility of an interplay between mast cell activation and kinin release during anaphylaxis and possibly angioedema. 32 None of our patients with ANGPT1 mutations ever experienced anaphylactic reactions, but we cannot exclude that this mutation could impair the activity of ANGPT1 on mast cells, influencing angioedema formation, anaphylactic reactions, or both.
Our data suggest that the p.A119S substitution results in a pathogenic loss of function of the protein, affecting the ability to form multimers. As a result, the mutant has a reduced ability to bind its specific receptor on endothelial cells, the TIE2 receptor.
We recognize the impairment of the endothelial ANGPT1-TIE2 ligand receptor system as a new pathophysiologic cause of U-HAE. Thus pharmaceutical agents that activate the TIE2 receptor pathway and lead to vascular stabilization might be useful to preserve endothelial barrier function and confer protection against vascular leakage. Our failure to identify the additional pathogenetic mutations in other families with U-HAE suggests the heterogeneity of this form of angioedema.
Key messages
d Among those with familial and sporadic U-HAE, the novel ANGPT1 p.A119S variant that cosegregated with the phenotype was identified in a large family.
d Natural and recombinant variant ANGPT1 proteins showed reduced capacity to form multimers and reduced ability to bind its natural receptor, TIE2.
